Description: GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Home Page: www.gbsciences.com
3550 West Teco Avenue
Las Vegas,
NV
89118
United States
Phone:
866 721 0297
Officers
| Name | Title |
|---|---|
| Mr. John Claybron Poss | Chairman & CEO |
| Dr. Andrea Small-Howard M.B.A., MBA, Ph.D. | Chairman of Scientific Advisory Board, Chief Science Officer, Pres & Director |
| Mr. Zach Swarts | CFO, Chief Accounting Officer & Treasurer |
| Mr. Krin Ellery Kuethe | Sr. VP of Cultivation |
| Mr. Gary R. Henrie Esq. | Securities Counsel & Company Sec. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0826 |
| Price-to-Sales TTM: | 1.9058 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 3 |